2026-06-11

HY spreads at distress levels — 705bps, recession-associated

Phase 3 trial terminated early — JOHNSON Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers

Phase 3 trial terminated early — JOHNSON A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patie

Phase 3 trial terminated early — JOHNSON A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus P

Phase 3 trial terminated early — JOHNSON A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With

Phase 3 trial terminated early — JOHNSON A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hyd

Phase 3 trial terminated early — ELI On Open-Label Study in Participants With Systemic Lupus Erythematosus

Phase 3 trial terminated early — ELI A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adole

Phase 3 trial terminated early — ELI A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Phase 3 trial terminated early — ELI Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

Phase 3 trial terminated early — BRISTOL An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness,

Phase 3 trial terminated early — BIOGEN Phase 3 Extension Study of Dexpramipexole in ALS

Phase 3 trial terminated early — BIOGEN Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclero

Phase 3 trial terminated early — BIOGEN Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma

Phase 3 trial terminated early — BIOGEN Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Pat

Phase 3 trial terminated early — BIOGEN A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With A

Phase 3 trial terminated early — AMGEN Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onse

Phase 3 trial terminated early — AMGEN Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or R

Phase 3 trial terminated early — INCYTE GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Gr

Phase 3 trial terminated early — INCYTE Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Phase 3 trial terminated early — REGENERON CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subje

Phase 3 trial terminated early — REGENERON Long Term Safety Study of PRALUENT

Phase 3 trial terminated early — REGENERON A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections

Phase 3 trial terminated early — REGENERON An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotr

Phase 3 trial terminated early — Medtronic Combining Observational and Physiologic Sedation Assessment Tools

Phase 3 trial terminated early — Medtronic Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Elut

Phase 3 trial terminated early — Medtronic Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients

Phase 3 trial terminated early — Medtronic X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suf

Phase 3 trial terminated early — Medtronic Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke

Phase 3 trial terminated early — AbbVie A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer P

FDA approves drug (AbbVie) — new revenue stream

Phase 3 trial terminated early — AbbVie Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Compl

FDA approves drug (AbbVie) — new revenue stream

Phase 3 trial terminated early — AbbVie A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Tr

FDA approves drug (AbbVie) — new revenue stream

Phase 3 trial terminated early — ABBOTT Kaletra and Viread in Antiretroviral Naïve Patients

Phase 3 trial terminated early — ABBOTT ESCAPE Migraine Trial

Phase 3 trial terminated early — ABBOTT Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemothera

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

Phase 3 trial terminated early — PFIZER Pregabalin for Abdominal Pain From Adhesions

FDA approves drug (PFIZER) — new revenue stream

Phase 3 trial terminated early — PFIZER Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of

Phase 3 trial terminated early — PFIZER Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN P

FDA approves drug (PFIZER) — new revenue stream

Phase 3 trial terminated early — PFIZER The Effect of Lipitor on Aortic Stenosis

Phase 3 trial terminated early — PFIZER Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection

FDA approves drug (PFIZER) — new revenue stream

Phase 3 trial terminated early — Merck A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With

Phase 3 trial terminated early — Merck Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doraviri

Phase 3 trial terminated early — Merck Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Particip

Phase 3 trial terminated early — Merck Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacterem

Phase 3 trial terminated early — Merck Alvimopan as Rescue in Post op Ileus

Phase 3 trial terminated early — Merck TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and A

Phase 3 trial terminated early — Merck Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

Phase 3 trial terminated early — GILEAD Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Pr

Phase 3 trial terminated early — GILEAD Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic

Phase 3 trial terminated early — GILEAD Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following P

Phase 3 trial terminated early — GILEAD Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants

CONOCOPHILLIPS search volume spiked +35 pts — unusual interest

5 congress members traded HUBB — net BEAR (0B/0S)

6 congress members traded TSCO — net BEAR (0B/0S)

5 congress members traded CHRW — net BEAR (0B/0S)

OSINT: Canada proposes ban on social media for under‑16s

CONOCOPHILLIPS search volume spiked +35 pts — unusual interest

5 congress members traded CHRW — net BEAR (0B/0S)

6 congress members traded TSCO — net BEAR (0B/0S)

5 congress members traded HUBB — net BEAR (0B/0S)

Missed consensus by 29.5% — EPS $-0.55 vs $-0.4246 estimate

Beat consensus by 20.6% — EPS $-0.26 vs $-0.3276 estimate

Missed consensus by 201.3% — EPS $-0.59 vs $-0.1958 estimate

Beat consensus by 106.0% — EPS $0.03 vs $-0.5042 estimate

Beat consensus by 7.4% — EPS $0.43 vs $0.4005 estimate

Beat consensus by 11.6% — EPS $0.41 vs $0.3674 estimate

Beat consensus by 15.5% — EPS $0.42 vs $0.3636 estimate

Beat consensus by 35.6% — EPS $-2.43 vs $-3.774 estimate

Missed consensus by 20.0% — EPS $-4.53 vs $-3.774 estimate

Beat consensus by 13.5% — EPS $-3.31 vs $-3.825 estimate

Beat consensus by 72.0% — EPS $-0.01 vs $-0.0357 estimate

Beat consensus by 311.8% — EPS $0.21 vs $0.051 estimate

Beat consensus by 118.4% — EPS $0.18 vs $0.0824 estimate

Missed consensus by 20.8% — EPS $1.21 vs $1.5278 estimate

Beat consensus by 11.8% — EPS $-0.03 vs $-0.034 estimate

Beat consensus by 77.7% — EPS $-0.01 vs $-0.0449 estimate

Beat consensus by 38.1% — EPS $-0.04 vs $-0.0646 estimate

Beat consensus by 26.5% — EPS $-0.02 vs $-0.0272 estimate

Missed consensus by 23.9% — EPS $-0.22 vs $-0.1775 estimate

Missed consensus by 144.5% — EPS $-0.49 vs $-0.2004 estimate

Missed consensus by 13.5% — EPS $-0.21 vs $-0.1851 estimate

Beat consensus by 11.5% — EPS $-0.17 vs $-0.1921 estimate

Beat consensus by 103.3% — EPS $0.55 vs $0.2706 estimate

Beat consensus by 5.5% — EPS $1.16 vs $1.0996 estimate

Beat consensus by 44.3% — EPS $-0.06 vs $-0.1078 estimate

Missed consensus by 6.2% — EPS $1.53 vs $1.6309 estimate

Beat consensus by 7.8% — EPS $1.76 vs $1.6334 estimate

Beat consensus by 28.8% — EPS $3.1 vs $2.4072 estimate

Missed consensus by 19.3% — EPS $2.37 vs $2.9376 estimate

Missed consensus by 29.4% — EPS $-0.04 vs $-0.0309 estimate

Missed consensus by 21.4% — EPS $-0.05 vs $-0.0412 estimate

Missed consensus by 1439.9% — EPS $-15.99 vs $1.1934 estimate

Missed consensus by 6707.4% — EPS $-27.08 vs $-0.3978 estimate

Missed consensus by 63.4% — EPS $-3.9 vs $-2.3868 estimate

Missed consensus by 126.9% — EPS $-4.93 vs $-2.1726 estimate

Beat consensus by 10.1% — EPS $-2.2 vs $-2.448 estimate

Beat consensus by 12.9% — EPS $-1.6 vs $-1.836 estimate

Missed consensus by 65.4% — EPS $-6.75 vs $-4.08 estimate

Missed consensus by 95.4% — EPS $-2.99 vs $-1.53 estimate

Missed consensus by 25.3% — EPS $-5.75 vs $-4.59 estimate

Missed consensus by 30.7% — EPS $-6.5 vs $-4.9725 estimate

Beat consensus by 8.4% — EPS $0.96 vs $0.8856 estimate

Beat consensus by 8.2% — EPS $0.89 vs $0.8222 estimate

Beat consensus by 9.3% — EPS $1.01 vs $0.9238 estimate

Missed consensus by 24.6% — EPS $-0.61 vs $-0.4896 estimate

Beat consensus by 13.2% — EPS $-0.5 vs $-0.5763 estimate

Missed consensus by 872.2% — EPS $-0.07 vs $-0.0072 estimate

Missed consensus by 38.9% — EPS $-0.01 vs $-0.0072 estimate

Beat consensus by 37.6% — EPS $-0.37 vs $-0.593 estimate

Beat consensus by 15.3% — EPS $-0.5 vs $-0.5906 estimate

Beat consensus by 31.3% — EPS $-0.37 vs $-0.5384 estimate

Beat consensus by 7.3% — EPS $58.86 vs $54.843 estimate

Beat consensus by 12.9% — EPS $62.25 vs $55.146 estimate

Missed consensus by 17.7% — EPS $53.3 vs $64.741 estimate

Beat consensus by 8.6% — EPS $1.53 vs $1.4089 estimate

Missed consensus by 6.1% — EPS $1.44 vs $1.5328 estimate

Beat consensus by 6.2% — EPS $1.55 vs $1.4601 estimate

Beat consensus by 86.6% — EPS $-1.11 vs $-8.2852 estimate

Beat consensus by 38.2% — EPS $-5.58 vs $-9.029 estimate

Missed consensus by 5.5% — EPS $107.61 vs $113.9187 estimate

Beat consensus by 30.4% — EPS $-5.75 vs $-8.2609 estimate

Beat consensus by 32.4% — EPS $-0.03 vs $-0.0444 estimate

Beat consensus by 24.0% — EPS $-0.05 vs $-0.0658 estimate

Beat consensus by 7.0% — EPS $-0.31 vs $-0.3333 estimate

Missed consensus by 13.9% — EPS $-0.23 vs $-0.202 estimate

Missed consensus by 146.9% — EPS $-0.09 vs $0.1919 estimate

Missed consensus by 68.4% — EPS $-0.67 vs $-0.3978 estimate

Beat consensus by 37.0% — EPS $-0.36 vs $-0.5712 estimate

Missed consensus by 111.2% — EPS $-1.12 vs $-0.5304 estimate

Beat consensus by 24.8% — EPS $-0.11 vs $-0.1462 estimate

Beat consensus by 24.0% — EPS $-0.1 vs $-0.1315 estimate

Beat consensus by 87.9% — EPS $-0.01 vs $-0.0825 estimate

Beat consensus by 63.1% — EPS $-0.06 vs $-0.1626 estimate

Beat consensus by 10.4% — EPS $1.76 vs $1.5948 estimate

Beat consensus by 7.3% — EPS $1.56 vs $1.4533 estimate

Beat consensus by 21.8% — EPS $1.63 vs $1.3378 estimate

Beat consensus by 155.8% — EPS $0.32 vs $-0.5739 estimate

Missed consensus by 76.8% — EPS $0.19 vs $0.8175 estimate

Missed consensus by 28.1% — EPS $-0.71 vs $-0.5541 estimate

Beat consensus by 20.9% — EPS $1.02 vs $0.8434 estimate

Beat consensus by 19.0% — EPS $-0.19 vs $-0.2346 estimate

Beat consensus by 209.4% — EPS $0.29 vs $-0.2652 estimate

Missed consensus by 108.3% — EPS $-0.34 vs $-0.1632 estimate

Missed consensus by 50.3% — EPS $-0.23 vs $-0.153 estimate

Missed consensus by 50.8% — EPS $-0.2 vs $-0.1326 estimate

Missed consensus by 35.7% — EPS $-0.09 vs $-0.0663 estimate

Missed consensus by 40.9% — EPS $-0.23 vs $-0.1632 estimate

Beat consensus by 13.9% — EPS $0.85 vs $0.7462 estimate

Missed consensus by 45.4% — EPS $0.47 vs $0.8613 estimate

Beat consensus by 122.2% — EPS $0.11 vs $0.0495 estimate

Missed consensus by 121.4% — EPS $-0.03 vs $0.1404 estimate

Missed consensus by 53.4% — EPS $0.05 vs $0.1072 estimate

Gold +3.18% — significant rally

OSINT: Explosion reported off Iran's southern coast near Sirik, cause unknown

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: US Signals Possible End to Birthright Citizenship

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: Iran launches >30 missiles at Jordan, ceasefire deemed void

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: US Strikes Trigger Blasts in Iran's Sirik, Raising Regional Tension

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

Oil -3.10% — significant selloff

Gold +1.29% — significant rally

SOL open interest -23.1% — OI collapse

BTC open interest -45.5% — OI collapse

ETH open interest -62.7% — OI collapse

ETH open interest +219.3% — OI surge

BTC open interest -42.5% — OI collapse

SOL open interest -64.4% — OI collapse

BTC open interest -47.3% — OI collapse

ETH open interest -62.7% — OI collapse

SOL open interest -21.6% — OI collapse

ETH open interest +229.2% — OI surge

SOL open interest +258.2% — OI surge

BTC open interest +228.8% — OI surge

VIX at 19.4 — CAUTION territory

VIX at 21.5 — CAUTION territory

OSINT: Canada proposes ban on social media for under‑16s

DXY +0.31% — dollar strength signal

DXY RSI 70.6 — overbought (crossed above 70)